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Abstract
Introduction: The majority of our knowledge regarding disease-related mechanisms of uncontrolled citrullination
and anti-citrullinated protein antibody development in rheumatoid arthritis (RA) was investigated in Caucasian
populations. However, peptidylarginine deiminase (PADI) type 4 gene polymorphisms are associated with RA in
East Asian populations and weak or no association was found in Caucasian populations. This study explores the
association between the PADI4 polymorphisms and RA risk in a multiethnic population residing in South East Asia
with the goal of elucidating generalizability of association in non-Caucasian populations.
Methods: A total of 320 SNPs from the PADI locus (including PADI1, PADI2, PADI3, PADI4 and PADI6 genes) were
genotyped in 1,238 RA cases and 1,571 control subjects from the Malaysian Epidemiological Investigation of
Rheumatoid Arthritis (MyEIRA) case-control study. Additionally, we conducted meta-analysis of our data together
with the previously published studies of RA from East Asian populations.
Results: The overall odds ratio (ORoverall) for the PADI4 (rs2240340) allelic model was 1.11 (95% confidence interval (CI)
= 1.00 to 1.23, P = 0.04) and for the genotypic model was 1.20 (95% CI = 1.01 to 1.44, P = 0.04). Haplotype analysis for
four selected PADI4 SNPs revealed a significant association of one with susceptibility (P = 0.001) and of another with a
protective effect (P = 0.02). The RA susceptibility was further confirmed when combined meta-analysis was performed
using these data together with data from five previously published studies from Asia comprising 5,192 RA cases and
4,317 control subjects (ORoverall = 1.23 (95% CI = 1.16 to 1.31, Pheterogeneity = 0.08) and 1.31 (95% CI = 1.20 to 1.44,
Pheterogeneity = 0.32) in allele and genotype-based models, respectively). In addition, we also detected a novel association
of PADI2 genetic variant rs1005753 with RA (ORoverall = 0.87 (95% CI = 0.77 to 0.99)).
Conclusion: Our study demonstrates an association between PADI4 and RA in the multiethnic population from
South East Asia and suggests additional association with a PADI2 gene. The study thus provides further support for
the notion that polymorphisms in genes for enzymes responsible for citrullination contribute to RA development in
multiple populations of Asian descent.
Introduction
Most studies of the association between rheumatoid arthri-
tis (RA) and genetic factors have focused on a group of
human leukocyte antigens in the major histocompatibility
complex [1] and a detailed account of the contributions
from different major histocompatibility complex genes and
their structural correlates was recently published for a
number of Caucasian populations [2]. Additional contribu-
tions from more than 30 different non-HLA loci have been
demonstrated, mainly in populations of Caucasian origin
[3]. Important differences for RA susceptibility genes
have, however, been described between Caucasian and
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non-Caucasian populations, as seen both from which HLA
alleles are associated with disease [4-7] and from associa-
tions with non-HLA genes. A particular interesting differ-
ence between Caucasian and Asian populations has been
demonstrated in genes from a peptidylarginine deiminase
(PADI) locus, where a polymorphism was first demon-
strated in a Japanese population [8] and later confirmed in
additional Japanese and Korean populations [9-12]. These
polymorphisms are of particular interest for the pathogen-
esis of RA since PADI4 and other PADI enzymes catalyze
change from peptidylarginine to peptidylcitrulline, a target
of anti-citrullinated protein antibody (ACPA), through a
post-translational modification process referred to as citrul-
lination [13,14].
The associations between PADI4 polymorphisms and
RA have so far focused on the Japanese and Korean popu-
lations [9,11,15]. The effect of PADI4 polymorphisms on
RA risk, however, remains unclear in the Han Chinese
population [16,17]. An association between PADI4 and
RA has also been observed in German and North Ameri-
can populations [18,19], while such an association has not
been replicated in other Caucasian populations (for exam-
ple, British, Spanish, Swedish and Hungarian) [19-23],
despite a comparable allele frequency between these Asian
and Caucasian populations. The largest study performed
in the UK population with over 19,000 subjects found no
evidence for association between the PADI4_94 SNP
(rs2240340) and RA. In a meta-analysis on previously pub-
lished European studies together with this UK study, the
association between the PADI4_94 genotype and RA was
weak and statistically not significant (odds ratio (OR) 1.06,
95% confidence interval (CI) = 0.99 to 1.13, P = 0.12) [23].
There is thus a need to further investigate the impact of
genetic variations in PADI-associated genes in additional
populations. Since ethnic differences are likely to go hand
in hand with different environmental exposures, it will be
helpful to study it in more divergent populations with
some similarities in genetic background.
The PADI gene region is located at chromosome 1p36.
This locus contains the cluster of all the PADI genes
(PADI1 to PADI4 and PADI6). Of the five isotypes of
PAD protein, PAD2 and PAD4 have been reported to be
expressed as active enzymes in RA synovium, where citrul-
lination of matrix proteins could potentially create anti-
genic peptides [24,25] and where increased citrullination
has been demonstrated in inflamed synovial tissues [26,27].
In the present study, which was performed in the South
East Asia region, the aimwas to determine whether the asso-
ciation between the PADI4 polymorphisms and RA risk
could be generalized to the Malaysian populations with
Malay, Chinese and Indian ethnicity. We also investigated
multiple SNPs from the locus (PADI1 to PADI4 and PADI6)
in this multiethnic case-control study involving early RA.
Materials and methods
Study population
The source of data for our investigation was the multicen-
ter Malaysian Epidemiological Investigation of Rheuma-
toid Arthritis (MyEIRA) case-control study, comprising
1,238 cases of RA and 1,571 control subjects. The demo-
graphic characteristics of RA cases and controls are shown
in Table 1. Of the 1,238 cases, 516 (41.7%) were Malays,
255 (20.6%) were Chinese, 379 (30.6%) were Indians and
88 (7.1%) were of other or mixed ethnicities from South
East Asia. The details of the MyEIRA study have been
described elsewhere [6]. Briefly, all RA cases were diag-
nosed by rheumatologists according to the 1987 revised
American College of Rheumatology criteria [28]. The dis-
ease duration for the RA cases was on average 1 year
(interquartile range = 2 years). For each potential case, a
control subject was randomly selected from the popula-
tion, taking into consideration the subject’s age, sex and
residential area. Of the 1,571 controls, 986 (62.8%) were
Malays, 206 (13.1%) were Chinese, 285 (18.1%) were
Indians and 94 (6.0%) were of other sub-ethnicities. We
performed case-control association analyses with regard to
the influence from different genetic factors for each ethnic
group separately as well as for the meta-analysis where all
four ethnic groups were included. The study was approved
by the Medical Research and Ethics Committee, Ministry
of Health, Malaysia, and written informed consent was
obtained from all participants.
Table 1 Demographic characteristics of rheumatoid arthritis patients and controls in the MyEIRA study population
Characteristic Malay Chinese Indian Others














Female 86.8 88.1 83.5 86.9 87.9 84.6 84.1 90.4
Age (years) 46 (11.8) 46 (11.4) 52 (11.2) 52 (11.3) 48 (11.6) 49 (10.6) 49 (12.1) 45 (11.7)
ACPA-positive 60.5 2.4 66.3 3.4 67.3 2.1 70.5 1.1
IgM RF-positive 47.5 3.8 49.4 3.4 55.9 5.3 62.5 6.4
IgG RF-positive 48.4 6.3 49.4 6.8 54.1 6.3 64.8 7.4
DRB1 SE-positivea 35.5 13.1 36.5 12.1 48.5 30.2 40.9 17.0
Data presented as percentage or mean (standard deviation). ACPA, anti-citrullinated protein antibody; MyEIRA, Malaysian Epidemiological Investigation of Rheumatoid
Arthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; SE, shared epitope. aPatients and controls carrying one or two alleles of a SE were classified as SE-positive.
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DNA extraction, selection of markers and genotyping
The genomic DNA was extracted using the QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany). All DNA sam-
ples were stored at -20°C until testing. We investigated
320 SNPs selected from the PADI locus on Immunochip
and from other studies [8,19-21,29]. The list of the geno-
typed PADI SNPs is presented in Table S1 in Additional
File 1. The SNPs were genotyped either using the TaqMan
SNP genotyping assay (Applied Biosystems, Foster City,
CA, USA) or by the Illumina iSelect HD custom genotyp-
ing array (Immunochip, Illumina, Inc, San Diego, CA,
USA). SNPs with call rates <95%, monomorphic SNPs,
SNPs with minor allele frequency <0.005, and SNPs with
Hardy-Weinberg equilibrium P <1.0 × 10-4 in RA cases
and controls were excluded from statistical evaluation.
This resulted in 227, 238, 263 and 248 SNPs passing qual-
ity-control filters for Malay, Chinese, Indian and other or
mixed ethnicities, respectively. Genetic outliers for each
ethnic group (that is, Malay, four cases and two controls;
Chinese, five cases and four controls; Indian, 10 cases)
were removed after principal component analysis to cor-
rect for possible population stratification.
To assess genotyping robustness, comparisons were
made between the TaqMan assay and the Illumina iSE-
LECT HD custom genotyping array (Immunochip) assay
regarding PADI4_94 (rs2240340), which resulted in a
100% match of the genotyping calls for both RA cases and
controls.
Genotyping for HLA-DRB1 shared epitope (SE) alleles -
defined by DRB1*01:01, DRB1*01:02, DRB1*01:07,
DRB1*04:01, DRB1*04:04, DRB1*04:05, DRB1*04:08,
DRB1*04:10, DRB1*10:01 and DRB1*10:03 alleles - was
performed by HLA-DRB1 high-resolution sequence-specific
oligonucleotide PCR for all the cases and controls as
described previously [6]. Individuals carrying one or two SE
alleles were classified as SE-positive [6].
Autoantibody measurements
ACPA and rheumatoid factors were identified and mea-
sured with ELISA kits (Immunoscan RA Mark 2; Euro-
Diagnostica, Malmö, Sweden) as described elsewhere [6].
Antibody levels ≥25 AU/ml and >15 IU/ml were regarded
as ACPA-positive and rheumatoid factor-positive,
respectively.
Statistical analysis
Genotype, allele and haplotype frequencies were assessed
with Yate’s chi-square and/or Fisher’s exact test when
appropriate by means of IBM SPSS Statistics 20.0 soft-
ware (SPSS Inc., Chicago, USA). The frequencies of the
alleles and genotypes of PADI SNPs were compared
between RA cases and control subjects and ORs with
95% CIs were calculated. Haplotype analysis was carried
out by Haploview [30]. Power calculation was performed
for a one-tail test at a significance level of 0.05. For meta-
analysis, the Mantel-Haenszel method was employed
with a fixed-effects model and 95% CI for cumulative or
overall odds ratio [31]. The significance of the cumulative
OR was determined by the Z-test. The between-study
heterogeneity was assessed using the Cochran Q-statistic
(P <0.10 considered significant). In addition, the I2 metric
[I2 = (Q - df)/Q] was used to describe the percentage of
variation across the studies due to heterogeneity.
I2 values of 25%, 50% and 75% were assigned as low,
moderate and high estimates, respectively.
Results
Characteristics of RA cases and controls
Among the RA cases, the overall mean ± standard devia-
tion age was 48 ± 11.6 years, 86.3% were female, 64.5%
were ACPA-positive, 40.1% were HLA-DRB1 SE-positive,
and 51.5% were rheumatoid factor-positive. The mean ±
standard deviation age of control subjects was 47 ± 11.4
years and 87.5% were female. The distribution of ethnic
groups (Malay, Chinese, Indian and other or mixed eth-
nicities) is shown in Table 1.
Evaluation of the PADI gene polymorphisms and RA
association in the MyEIRA study
Collectively, our study has 88% statistical power to detect
genotype/minor allele frequency differences of the mag-
nitude reported in the initial positive study in a Japanese
population [8].
Overall, the single-point analyses of variations in the
PADI1, PADI2, PADI3, PADI4 and PADI6 genes
revealed a modest genetic effect size in the RA popula-
tion and showed that the peak association varies between
different ethnic groups. For example, the rs2526839 var-
iant showed the peak association signal in Malay RA
patients (OR = 1.24, 95% CI = 1.04 to 1.43, P = 0.0126),
the rs3003444 variant in Chinese RA patients (OR = 1.60,
95% CI = 1.20 to 2.13, P = 0.0013) and the rs113475583
variant in Indian RA patients (OR = 1.91, 95% CI = 1.19
to 3.07, P = 0.0064) (see Figure S1 in Additional File 1).
PADI2 gene polymorphism as a risk factor in RA
development
The PADI2 gene encodes PAD2 enzyme, which is the
most widely expressed family member of PAD. An asso-
ciation between RA and the PADI2 variant was found in
a Korean population [32]. We undertook this study for
further investigation of whether PADI2 polymorphisms
are also at risk for RA development in three indepen-
dent Asian populations. Interestingly, the PADI2 variant
meta-analysis demonstrated a possible novel association
of the PADI2 rs1005753 variant with RA, both in the
allelic model (ORoverall = 0.88, 95% CI = 0.77 to 0.99,
P = 0.04) and in the dominant/recessive genotype model
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(ORoverall = 0.84, 95% CI = 0.72 to 0.99, P = 0.04)
(Figure 1). In this multiethnic case-control study, no evi-
dence of heterogeneity was found for the PADI2
rs1005753 variant (Pheterogeneity = 0.43, I
2 = 0%).
Generalizability of PADI4 gene polymorphisms as a risk
factor in RA development
A summary of the MyEIRA meta-analysis for the PADI4
polymorphism with RA is presented in Figure 2. The
MyEIRA meta-analysis suggests an association of the
PADI4 rs2240340 variant with RA also found in the
Malaysian population (ORoverall = 1.11, 95% CI = 1.00 to
1.23, P = 0.04). The meta-analysis also revealed a signifi-
cantly increased OR (ORoverall = 1.20, 95% CI = 1.01 to
1.44, P = 0.04) when applying a dominant/recessive gen-
otype model for the PADI4 rs2240340 variant, suggest-
ing that the PADI4 is associated with RA in the
Malaysian population of Asian descent.
To clarify the role of the PADI4 gene as a possible
susceptibility factor for RA development in different
Asian ethnic populations, we performed a combined
meta-analysis using our current data together with the
previously published studies from Asia. We searched
information from the PubMed database, ISI Web of
Knowledge and Google. Six published original case-con-
trol studies related to PADI4 polymorphisms in RA in
three different Asian populations were identified: three
Japanese studies including the first positive report, one
Korean study and two Chinese studies [8-11,16,17]. All
studies had used the defined American College of Rheu-
matology criteria [28] for the diagnosis of RA as com-
pared with our study. The strongest evidence of
association reported in the first study was given by
PADI4_94 (rs2240340); we therefore restricted the cur-
rent combined meta-analysis to this genetic variant. Of
the six published papers, the Korean study did not geno-
type for PADI4 rs2240340. Instead, we used genotype
data of PADI4_89 (rs11203366). This choice was made
because these SNPs are in strong linkage disequilibrium
(r2 = 1.00) and the minor allele frequency of these SNPs
are nearly equal according to the International Human
Genome Project Chinese and Japanese populations
(International HapMap CHB + JPT) (Asian population).
Five studies were included in the combined meta-analy-
sis together with our new data for PADI4 rs2240340
[8-11,16]. The PADI4 SNPs investigated in Fan and
Figure 1 Allelic association between PADI2 rs1005753 polymorphism and risk of rheumatoid arthritis in the MyEIRA study.
Meta-analysis of the minor allele (rs1005753_G) versus the common allele (rs1005753_T). CI, confidence interval; MH, Mantel-Haenszel; phet, P value for
heterogeneity; I2, degree of heterogeneity (%); MyEIRA, Malaysian Epidemiological Investigation of Rheumatoid Arthritis; PADI, peptidylarginine
deiminase.
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colleagues’ study were not analyzed because they exhib-
ited significant deviation from Hardy-Weinberg equili-
brium (P <0.001) [17], which questions the validity of
the genotyping data.
In total, the combined meta-analysis of the PADI4
rs2240340 included 5,192 RA cases and 4,317 control sub-
jects from Asian populations. The Mantel-Haenszel
method with fixed effects exhibited significant ORs in
both the allelic model (OR = 1.23, 95% CI = 1.16 to 1.31,
P <10-4) and the dominant/recessive genotype model (OR
= 1.31, 95% CI = 1.20 to 1.44, P <10-4) (Figure 3a, b). A
moderate level of between-study heterogeneity was
observed in the allele model (Pheterogeneity = 0.08, I
2 =
44%), but not in the genotype model (Pheterogeneity = 0.32,
I2 = 14%). With the exclusion of the initial positive report,
which tends to suggest a stronger genetic effect (winner’s
curse) than those in subsequent studies [9-11,16], the
cumulative OR decreased slightly but remained highly sig-
nificant (P <10-4) with no significant heterogeneity (Phetero-
geneity = 0.47, I
2 = 0%) (see Figure 3 caption).
Stratified analysis
Stratified analyses were performed to detect association
between the PADI gene variants and RA risk within spe-
cific population subgroups as well as in relation to more
homogeneous subsets of RA cases. Stratifying by sex, car-
riage of SE alleles, presence of ACPA or presence of
rheumatoid factors among the cases revealed no evidence
of different associations between the compared sub-
groups (data not shown). Nevertheless, it is noteworthy
that a set of different SNPs variants were associated with
risk of developing ACPA-positive and ACPA-negative
RA within specific subpopulations, although the results
were not significant after correction for multiple compar-
isons (Table 2). It would be interesting to investigate the
association between RA and these SNP variants in other
populations with more data.
Haplotype analysis and association test
We first performed the univariate single-population ana-
lyses for the association of PADI SNPs with RA, and sub-
sequently those SNPs with statistical significant effects
were selected for further haplotype analysis. However, we
excluded the SNPs with inconsistent effects within the
four ethnic groups, and also those SNPs with a significant
level not low enough (P <0.05) in one or more ethnic
groups. This analysis strategy led us to four PADI4 SNPs
for haplotype analysis (rs79907974, rs2240340, rs1748021
and rs2240337). When haplotypes were constructed using
these four PADI4 SNPs, seven haplotypes with frequency
>1% out of 16 expected haplotypes were found in the
study populations (Table 3). Haplotype GCGG was
omitted from the association test because it was only
found in the Indian ethnic group with a frequency of 5%.
When meta-analyses for different ethnic groups in our
study were conducted, ATAA and ATAG showed a
Figure 2 Allelic association between PADI4 rs2240340 polymorphism and risk of rheumatoid arthritis in the MyEIRA study.
Meta-analysis of the minor allele (rs2240340_T) versus the common allele (rs2240340_C). CI, confidence interval; MH, Mantel-Haenszel; phet, P value for
heterogeneity; I2, degree of heterogeneity (%); MyEIRA = Malaysian Epidemiological Investigation of Rheumatoid Arthritis; PADI, peptidylarginine
deiminase.
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Figure 3 Allelic and genotypic association between PADI4 rs2240340 polymorphism and rheumatoid arthritis in Asian populations.
Combined meta-analysis of (a) the allelic model and (b) the genotypic model between PADI4 rs2240340 polymorphism and risk of developing
RA in Asian populations. (a) *If the first Japanese study was excluded, overall odds ratio (ORoverall) = 1.21 (1.13 to 1.29), phet = 0.15, I
2 = 35%; **if
the Korean study was excluded as the PADI4 rs2240340 SNP was not investigated, ORoverall = 1.21 (1.13 to 1.29), phet = 0.23, I
2 = 25%; if both the
first Japanese study and the Korean study were excluded, ORoverall = 1.17 (1.09 to 1.25), phet = 0.58, I
2 = 0%. (b) *If the first Japanese study was
excluded, ORoverall = 1.27 (1.15 to 1.40), phet = 0.47, I
2 = 0%; **if the Korean study was excluded as the PADI4 rs2240340 SNP was not
investigated, ORoverall = 1.28 (1.16 to 1.40), phet = 0.58, I
2 = 0%; if both the first Japanese study and the Korean study were excluded, ORoverall =
1.22 (1.10 to 1.35), phet = 0.93, I
2 = 0%. Minor allele (rs2240340_T) versus common allele (rs2240340_C). CI, confidence interval; MH, Mantel-
Haenszel; phet, P value for heterogeneity; I
2, degree of heterogeneity expressed as percentage; RA, rheumatoid arthritis.
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significant difference between RA cases and controls (P =
0.02 and P = 0.001, respectively; Table 3) with no signifi-
cant heterogeneity (Pheterogeneity = 0.78, I
2 = 0%). These
haplotypes represent either protective (ATAA) or suscep-
tible (ATAG) variants. We further tested these haplotype
associations with different RA subsets defined by ACPA
status. The results showed consistent effects in the RA
subsets, and the ORoverall was comparable between ACPA-
positive and ACPA-negative RA subsets (see Table S2 in
Additional File 1).
Discussion
In this study, we used a multiethnic population of Asian
descent in Malaysia to determine the association between
PADI4 polymorphisms and risk of RA, and convincingly
validated this association. Our current data, together
with the previously published data on Asian populations,
strongly support PADI4 as a RA susceptibility gene in
different ethnic populations of Asian descent. Collec-
tively, our data extend previous results on PADI4 and RA
based on Asian populations, mainly in Japanese and Kor-
ean populations [8-11,15,33], to be observed in another
population of Asian origin (that is, Malay, Chinese and
Indian ethnicity). Notably, a possible novel association
between the PADI2 genetic variant and RA risk was also
found in the multiethnic Malaysian population.
The combined meta-analysis was performed regardless
of the ACPA status, since such data were not available in
the previous published papers. However, our present
study showed a comparable minor allele frequency
between the RA subsets defined by ACPA status, thus
suggesting that the risk from PADI locus is likely to be
common for the two main subgroups of RA.
Previously, the association studies of the PADI4 poly-
morphism and RA found in Asian populations were pre-
dominantly focused on Japanese and Korean populations
[8-11,15], which are geographically and historically clo-
sely related and genetically quite similar to each other
[34]. The results, however, were inconsistent across two
independent studies in Han Chinese populations [16,17].
Malaysia is a multiethnic country in South East Asia
representing genetic diversity across multiple large ethnic
populations of Asian origin (that is, Malays, Chinese and
Indians). In our study, we were able to address the ques-
tion of whether PADI4 polymorphisms confer a risk of
RA in this diverse population. We found that the
PADI4_94 polymorphism is associated with an increased
risk of developing RA in this population. Interestingly, as
can be seen from Figure 3, the effect for the Han Chinese
population is probably lower than for other Asian popu-
lations, which may be an explanation for previous incon-
sistency in published data.
Haplotype analysis did not reveal a higher effect size in
comparison with univariate SNP analyses in our study.
Nevertheless, meta-analysis of PADI4 haplotypes with
the current data implied that association with RA was
Table 2 Significant SNP variants associated with ACPA-positive and ACPA-negative RA in the MyEIRA study population
Ethic group SNP variant Risk allele Ratio counts (case, control) Frequencies (case, control) c2 P value
ACPA-positive RA
Malay rs12042956 G 50:562, 103:1819 0.082, 0.054 6.465 0.011
Malay rs7538876 G 496:122, 1480:478 0.803, 0.756 5.738 0.0166
Malay rs2526839 C 240:378, 667:1291 0.388, 0.341 4.684 0.0304
Chinese rs3003444 A 247:83, 262:142 0.748, 0.649 8.539 0.0035
Chinese rs2977299 G 223:107, 235:169 0.676, 0.582 6.851 0.0089
Chinese rs3766298 A 223:107, 234:168 0.676, 0.582 6.779 0.0092
Indian rs113475583 G 481:21, 532:44 0.958, 0.924 5.653 0.0174
Indian rs72633848 A 483:21, 536:44 0.958, 0.924 5.594 0.018
Indian rs35903413 G 498:6, 564:16 0.988, 0.972 3.335 0.0678
ACPA-negative RA
Malay rs16825533 G 67:337, 227:1731 0.166, 0.116 7.654 0.0057
Malay rs57744451 G 67:339, 234:1724 0.165, 0.120 6.269 0.0123
Malay rs2240337 G 388:14, 1826:128 0.965, 0.934 5.541 0.0186
Chinese rs3003444 A 125:43, 262:142 0.744, 0.649 4.949 0.0261
Chinese rs12037558 A 113:53, 237:167 0.681, 0.587 4.395 0.036
Chinese rs2977296 G 145:23, 320:84 0.863, 0.792 3.935 0.0473
Indian rs12042956 A 223:13, 506:64 0.945, 0.888 6.319 0.0119
Indian rs2977305 A 242:4, 550:26 0.984, 0.955 4.088 0.0432
Indian rs34324150 G 242:4, 552:26 0.984, 0.955 4.058 0.044
Top three significant SNP variants associated with risk of developing anti-citrullinated protein autoantibody (ACPA)-positive and ACPA-negative rheumatoid
arthritis (RA) in three major ethnic groups from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA) study population
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Table 3 Haplotype frequencies and meta-analysis of PADI4 polymorphisms in relation to RA in the MyEIRA study
Block Ethnicity Haplotype frequency Ratio counts (case, control) Frequencies (case, control) c2 P value OR (95% CI) Meta-analysis Phet I2 (%)
ACGG Malay 0.501 510.8:537.2, 984.2:951.8 0.487, 0.508 1.195 0.2744 0.92 (0.79 to 1.07) 0.91 (0.82 to 1.02), Z = 1.62 (P = 0.10) 0.64 0
Chinese 0.567 288.8:217.2, 224.7:175.3 0.571, 0.562 0.076 0.7835 1.04 (0.80 to 1.35)
Indian 0.413 292.7:453.3, 246.1:313.9 0.392, 0.439 2.919 0.0875 0.83 (0.66 to 1.03)
Others 0.46 78.8:97.2, 88.6:99.4 0.447, 0.471 0.204 0.6519 0.91 (0.60 to 1.37)
ATAA Malay 0.055 42.5:1,005.5, 120.7:1,815.3 0.041, 0.062 6.226 0.0126 0.64 (0.45 to 0.92) 0.71 (0.54-0.94), Z = 2.42 (P = 0.02) 0.78 0
Chinese 0.064 29.0:477.0, 29.0:371.0 0.057, 0.073 0.86 0.3537 0.78 (0.46 to 1.32)
Indian 0.015 9.7:736.3, 9.3:550.7 0.013, 0.017 0.293 0.5886 0.83 (0.34 to 2.06)
Others 0.039 7.3:168.7, 7.0:181.0 0.042, 0.037 0.046 0.8296 1.07 (0.37 to 3.12)
ATAG Malay 0.287 333.6:714.4, 522.9:1,413.1 0.318, 0.270 7.736 0.0054 1.26 (1.07 to 1.49) 1.21 (1.08-1.36), Z = 3.20 (P = 0.001) 0.78 0
Chinese 0.274 140.8:365.2, 107.1:292.9 0.278, 0.268 0.128 0.7202 1.06 (0.79 to 1.42)
Indian 0.398 312.4:433.6, 207.6:352.4 0.419, 0.371 3.09 0.0788 1.22 (0.97 to 1.52)
Others 0.34 62.5:113.5, 61.4:126.6 0.355, 0.326 0.336 0.562 1.16 (0.75 to 1.79)
ATGG Malay 0.096 108.7:939.3, 178.8:1,757.2 0.104, 0.092 1.001 0.317 1.14 (0.89 to 1.46) 1.02 (0.77-1.36), Z = 0.14 (P = 0.89) 0.24 29
Chinese 0.046 23.2:482.8, 18.3:381.7 0.046, 0.046 0.0 0.9908 1.01 (0.54 to 1.90)
Indian 0.049 39.1:706.9, 25.3:534.7 0.052, 0.045 0.351 0.5538 1.18 (0.71 to 1.97)
Others 0.091 11.0:165.0, 22.0:166.0 0.063, 0.117 3.268 0.0706 0.50 (0.24 to 1.07)
GTAG Malay 0.041 38.6:1,009.4, 83.8:1,852.2 0.037, 0.043 0.714 0.398 0.85 (0.58 to 1.26) 0.94 (0.72-1.21), Z = 0.49 (P = 0.63) 0.59 0
Chinese 0.042 20.1:485.9, 17.9:382.1 0.040, 0.045 0.138 0.7099 0.87 (0.46 to 1.67)
Indian 0.065 47.9:698.1, 37.1:522.9 0.064, 0.066 0.023 0.8798 0.97 (0.62 to 1.51)
Others 0.046 10.4:165.6, 6.4:181.6 0.059, 0.034 1.326 0.2496 1.83 (0.65 to 5.14)
















probably driven by the rs2240337 variant. This genetic
variant, however, has low minor allele frequency in our
materials (that is, minor allele frequency in Malay =
0.059, Chinese = 0.066, Indian = 0.032 and others =
0.042). Noteworthy is that this SNP variant, on the con-
trary, is in complete linkage disequilibrium (D’ = 1.00)
with the PADI4 SNP rs766499 variant, which was
reported recently to be associated with the Japanese RA
population at a genome-wide level of significance in
meta-analysis [12].
An additional novel finding in our study is the discovery
of a possible association between the PADI2 genetic var-
iant (rs1005753) and RA, which was observed both in
allele and genotype models. The genetic effect observed is
possibly due to an indirect association, where the identi-
fied genetic variants (that is, PADI2) by themselves are not
functional but are in linkage disequilibrium with a causal
variant polymorphism such as the PADI4 gene. However,
this would be unlikely as the PADI2 genetic variant
(rs1005753) did not show any linkage disequilibrium with
the numerous investigated SNPs spanning between PADI1
and PADI6 in the present study. We observed r2 <0.01 for
all ethnic groups studied. A previous study by Freudenberg
and colleagues reported an association between the PADI2
genetic variant (rs2075696) and RA in a Korean study [32].
Interestingly, the rs1005753 variant associated in our study
and the rs2075696 variant are located in two different link-
age disequilibrium blocks in the PADI2 gene locus. The
International HapMap CHB+JPT project showed no link-
age disequilibrium relationship between these two SNPs
(D’ = 0.0050, r2 = 0.0). Together, our data may suggest a
possible risk effect between the rs1005753 variant and RA
in the Malaysian population.
Worthy of mention is that PADI2 and PADI4 are the
only two genes that are highly expressed in hemapoetic
cells [35]. In RA, the expression levels of PAD2 and
PAD4 were correlated with the intensity of inflammation,
and both enzymes were demonstrable within or in the
vicinity of citrullinated fibrins deposits [36]. The PADI2
gene encodes the PAD2 enzyme, is perhaps playing a role
in RA pathogenesis on its own, independently from
PADI4. Nevertheless, it is important to perform further
extension of the study to gain better statistical power to
investigate this association in a single-population analysis
and further to replicate the association in independent
cohorts of Asian origin. Since the difference between
Caucasian and Asian populations may represent both
genetic and environmental heterogeneity, it is logical to
propose a gene-environmental interaction study for
PADI genes in the development of RA.
Conclusion
This study demonstrates an association between PADI4
polymorphisms and RA in the Malaysian population.
The currently updated combined meta-analysis of Asian
populations further supports the hypothesis that the
PADI locus contributes to the development of RA in
different Asian populations and that this genetic effect is
generalized to multiple ethnic populations of Asian
descent.
Additional material
Additional file 1: Table S1 presenting a list of PADI SNPs
investigated in the MyEIRA study population. A complete set of 320
SNPs selected from the PADI locus on Immunochip and from other
studies. The SNPs were genotyped either using the TaqMan SNP
genotyping assay (Applied Biosystems, USA) or by Illumina iSELECT HD
custom genotyping array (Immunochip). Table S2 presenting the
haplotype frequencies and meta-analysis of PADI4 polymorphisms in the
MyEIRA study by ACPA status. The haplotype analysis and meta-analysis
of PADI4 polymorphisms in the MyEIRA study were performed in
different subsets of RA defined by ACPA status. Bold results indicate
significant association between the PADI haplotypes and subsets of RA.
Figure S1 showing the regional association plots with recombination rate
on the PADI genes for the three major ethnic groups from the MyEIRA
study. Regional association plots on the PADI genes including PADI1,
PADI2, PADI3, PADI4 and PADI6 for the three major ethnic groups from
MyEIRA study showing the peak association in each ethnic group. Graphs
centered on the most significant SNP in each ethnic group. The r2 values
(linkage disequilibrium between the most significant SNP and the rest of
SNPs in the region) are calculated on the MyEIRA data and the
recombination rates are based on the International HapMap CHB+JPT
data.
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